CN108066338B - 抗生素组合物及其制备方法 - Google Patents
抗生素组合物及其制备方法 Download PDFInfo
- Publication number
- CN108066338B CN108066338B CN201711433711.8A CN201711433711A CN108066338B CN 108066338 B CN108066338 B CN 108066338B CN 201711433711 A CN201711433711 A CN 201711433711A CN 108066338 B CN108066338 B CN 108066338B
- Authority
- CN
- China
- Prior art keywords
- metronidazole
- cefuroxime sodium
- injection
- impurity
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 20
- 239000000203 mixture Substances 0.000 title claims description 6
- 230000003115 biocidal effect Effects 0.000 title description 5
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 claims abstract description 163
- 229960000534 cefuroxime sodium Drugs 0.000 claims abstract description 162
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 119
- 229960000282 metronidazole Drugs 0.000 claims abstract description 119
- 238000002347 injection Methods 0.000 claims abstract description 100
- 239000007924 injection Substances 0.000 claims abstract description 100
- 239000003814 drug Substances 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 208000003322 Coinfection Diseases 0.000 claims abstract description 10
- 241001148470 aerobic bacillus Species 0.000 claims abstract description 10
- 241001148471 unidentified anaerobic bacterium Species 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 83
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 73
- 239000012535 impurity Substances 0.000 claims description 53
- 230000001954 sterilising effect Effects 0.000 claims description 45
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 229920005549 butyl rubber Polymers 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- 229910021645 metal ion Inorganic materials 0.000 claims description 20
- 239000008139 complexing agent Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 239000012046 mixed solvent Substances 0.000 claims description 14
- 239000002510 pyrogen Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 238000001291 vacuum drying Methods 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 10
- 229930182555 Penicillin Natural products 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- 229940049954 penicillin Drugs 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000013078 crystal Substances 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000007974 sodium acetate buffer Substances 0.000 claims description 6
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical group [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 claims description 4
- HSCOLDQJZRZQMV-UHFFFAOYSA-N 1-Methyl-4-nitroimidazole Chemical compound CN1C=NC([N+]([O-])=O)=C1 HSCOLDQJZRZQMV-UHFFFAOYSA-N 0.000 claims description 4
- RSXWJXPKLRYMHW-UHFFFAOYSA-N 2-(2-methyl-4-nitroimidazol-1-yl)ethanol Chemical compound CC1=NC([N+]([O-])=O)=CN1CCO RSXWJXPKLRYMHW-UHFFFAOYSA-N 0.000 claims description 4
- UGPDZGBXWBKFMT-UHFFFAOYSA-N 2-[2-(2-methyl-5-nitroimidazol-1-yl)ethoxy]ethanol Chemical compound CC1=NC=C([N+]([O-])=O)N1CCOCCO UGPDZGBXWBKFMT-UHFFFAOYSA-N 0.000 claims description 4
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 2
- QGQXAMBOYWULFX-LZWSPWQCSA-N 2-morpholin-4-ylethyl (e)-6-(4,6-dihydroxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound OC=1C=2C(=O)OCC=2C(C)=C(O)C=1C\C=C(/C)CCC(=O)OCCN1CCOCC1 QGQXAMBOYWULFX-LZWSPWQCSA-N 0.000 claims 1
- UEAVLBXLOZNDHT-UHFFFAOYSA-K calcium;sodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical group [Na+].[Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEAVLBXLOZNDHT-UHFFFAOYSA-K 0.000 claims 1
- 238000005096 rolling process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 15
- 208000015181 infectious disease Diseases 0.000 abstract description 15
- 229960001668 cefuroxime Drugs 0.000 abstract description 5
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 abstract description 5
- 229940087281 cefuroxime and metronidazole Drugs 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 description 40
- 230000008569 process Effects 0.000 description 23
- 239000000047 product Substances 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 229910052799 carbon Inorganic materials 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 239000002245 particle Substances 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 238000000227 grinding Methods 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 229910052782 aluminium Inorganic materials 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 description 6
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000003455 anaphylaxis Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 102000006635 beta-lactamase Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- -1 polydimethylsiloxane Polymers 0.000 description 5
- 238000007670 refining Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- BXWLVQXAFBWKSR-UHFFFAOYSA-N 2-methoxy-5-methylsulfonylbenzoic acid Chemical compound COC1=CC=C(S(C)(=O)=O)C=C1C(O)=O BXWLVQXAFBWKSR-UHFFFAOYSA-N 0.000 description 4
- 108090000204 Dipeptidase 1 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000005388 borosilicate glass Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 229950004777 sodium calcium edetate Drugs 0.000 description 3
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000606124 Bacteroides fragilis Species 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000186394 Eubacterium Species 0.000 description 2
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- 241000206591 Peptococcus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010067268 Post procedural infection Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 2
- 229960002727 cefotaxime sodium Drugs 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000003749 cleanliness Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- OUSLHGWWWMRAIG-FBCAJUAOSA-N (6r,7r)-7-[[(2z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(CO)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 OUSLHGWWWMRAIG-FBCAJUAOSA-N 0.000 description 1
- NVIAYEIXYQCDAN-MHTLYPKNSA-N (6r,7s)-7-azaniumyl-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S1CC(C)=C(C([O-])=O)N2C(=O)[C@H]([NH3+])[C@@H]12 NVIAYEIXYQCDAN-MHTLYPKNSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000289690 Xenarthra Species 0.000 description 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000009804 total hysterectomy Methods 0.000 description 1
- 229910021655 trace metal ion Inorganic materials 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003952 β-lactams Chemical group 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
试验条件 | 3月 | 6月 | 9月 | 12月 | 18月 | 24月 | 30月 |
含量 | 99.2% | 99.0% | 98.7% | 98.2% | 97.9% | 97.2% | 96.3% |
总杂 | 0.12% | 0.14% | 0.18% | 0.28% | 0.35% | 0.49% | 0.62% |
序号 | 内毒素/热原水平 |
1 | <0.25EU |
2 | <0.25EU |
3 | <0.25EU |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711433711.8A CN108066338B (zh) | 2017-12-26 | 2017-12-26 | 抗生素组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711433711.8A CN108066338B (zh) | 2017-12-26 | 2017-12-26 | 抗生素组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108066338A CN108066338A (zh) | 2018-05-25 |
CN108066338B true CN108066338B (zh) | 2020-04-24 |
Family
ID=62155227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711433711.8A Active CN108066338B (zh) | 2017-12-26 | 2017-12-26 | 抗生素组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108066338B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111494314B (zh) * | 2020-06-01 | 2022-05-24 | 上海信谊金朱药业有限公司 | 一种盐酸氨溴索口服溶液及其制备方法 |
CN114652716B (zh) * | 2022-03-31 | 2023-01-31 | 中国农业科学院兰州畜牧与兽药研究所 | 地美硝唑在制备抗β-内酰胺类耐药性大肠杆菌药物中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1830439A (zh) * | 2005-03-08 | 2006-09-13 | 巴里莫尔制药(通化)有限公司 | 一种甲硝唑冻干粉针剂的制备方法 |
CN101475579A (zh) * | 2009-01-20 | 2009-07-08 | 广州白云山天心制药股份有限公司 | 一种稳定的头孢呋辛钠及其制备方法 |
CN101491502A (zh) * | 2008-10-24 | 2009-07-29 | 邢建荣 | 头孢呋辛钠冻干粉及其制备方法 |
CN102274167A (zh) * | 2011-07-20 | 2011-12-14 | 蚌埠丰原涂山制药有限公司 | 甲硝唑氯化钠注射液的制备方法 |
CN102525905A (zh) * | 2012-02-13 | 2012-07-04 | 河南天方华中药业有限公司 | 一种替硝唑氯化钠注射液及其制备方法 |
CN104774211A (zh) * | 2015-04-27 | 2015-07-15 | 四川制药制剂有限公司 | 注射用头孢呋辛钠的制备工艺 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8320520D0 (en) * | 1983-07-29 | 1983-09-01 | Glaxo Group Ltd | Chemical process |
CN1238911A (zh) * | 1999-01-07 | 1999-12-22 | 鹿瑞麟 | 一种生物制品防腐剂 |
US7064198B2 (en) * | 2001-07-25 | 2006-06-20 | Lupin Limited | Method for preparation of cefuroxime axetil |
CN100564382C (zh) * | 2006-11-12 | 2009-12-02 | 西南合成制药股份有限公司 | 头孢呋辛钠的合成方法 |
CN103044452A (zh) * | 2013-01-10 | 2013-04-17 | 潘行远 | 一种低水分、高稳定性的无菌头孢呋辛钠的制备方法 |
-
2017
- 2017-12-26 CN CN201711433711.8A patent/CN108066338B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1830439A (zh) * | 2005-03-08 | 2006-09-13 | 巴里莫尔制药(通化)有限公司 | 一种甲硝唑冻干粉针剂的制备方法 |
CN101491502A (zh) * | 2008-10-24 | 2009-07-29 | 邢建荣 | 头孢呋辛钠冻干粉及其制备方法 |
CN101475579A (zh) * | 2009-01-20 | 2009-07-08 | 广州白云山天心制药股份有限公司 | 一种稳定的头孢呋辛钠及其制备方法 |
CN102274167A (zh) * | 2011-07-20 | 2011-12-14 | 蚌埠丰原涂山制药有限公司 | 甲硝唑氯化钠注射液的制备方法 |
CN102525905A (zh) * | 2012-02-13 | 2012-07-04 | 河南天方华中药业有限公司 | 一种替硝唑氯化钠注射液及其制备方法 |
CN104774211A (zh) * | 2015-04-27 | 2015-07-15 | 四川制药制剂有限公司 | 注射用头孢呋辛钠的制备工艺 |
Non-Patent Citations (2)
Title |
---|
甲硝唑注射液与注射用头孢呋辛钠配伍稳定性考察;韩莹旻;《实用药物与临床》;20050220;参见摘要,第1节和第2.2节 * |
韩莹旻.甲硝唑注射液与注射用头孢呋辛钠配伍稳定性考察.《实用药物与临床》.2005, * |
Also Published As
Publication number | Publication date |
---|---|
CN108066338A (zh) | 2018-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2062582B1 (en) | Antibiotic composition comprising beta-lactam antibiotics, aminoglycosides and buffers | |
CN102895181B (zh) | 注射用美洛西林钠的制备方法 | |
CN101080230A (zh) | 包括囊性纤维化的严重感染的治疗和控制 | |
CN108066338B (zh) | 抗生素组合物及其制备方法 | |
CN102451154A (zh) | 硫酸奈替米星注射液及其制备方法 | |
CN101637447B (zh) | 一种西他沙星注射剂及其制备方法 | |
CN102860980A (zh) | 一种罗库溴铵注射液的制备方法 | |
CN108096198A (zh) | 预防和治疗需氧菌与厌氧菌混合感染时的新型抗菌药物组合物及其制备方法 | |
CN101912361B (zh) | 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 | |
CN103232477B (zh) | 一种盐酸头孢替安化合物、其制备方法及其药物组合物 | |
CN103110640B (zh) | 一种注射用头孢唑肟钠和复方氨基酸注射液的药物组合物 | |
CN105147599B (zh) | 硫酸奈替米星注射液和制法 | |
CN104644551A (zh) | 一种供注射用的含有盐酸法舒地尔的药物组合物 | |
CN104644572B (zh) | 一种高纯度克林霉素磷酸酯粉针剂及其制备工艺 | |
CN110393720B9 (zh) | 曲索芬头孢曲松钠化合物药物制剂及治疗免疫机能低下患者感染的新适应症 | |
CN101904822B (zh) | 一种法罗培南钠冻干粉针及其制备方法 | |
CN102688183A (zh) | 一种稳定的盐酸莫西沙星注射剂 | |
CN105213301B (zh) | 硫酸奈替米星注射液及其质控方法 | |
CN100508982C (zh) | 一种含有头孢曲松钠和盐酸利多卡因的注射用药物组合物 | |
CN110396104B (zh) | 泰司汀头孢他啶药物制剂治疗妇科感染的新适应症 | |
CN103304580B (zh) | 一种盐酸头孢吡肟化合物、其制备方法及其药物组合物 | |
CN110893173A (zh) | 一种注射用头孢他啶粉针剂及其制备方法 | |
CN102204888B (zh) | 一种含头孢孟多酯钠化合物的药物组合物及其制备方法 | |
CN113069422B (zh) | 注射用头孢拉宗钠冻干粉针剂的制备方法 | |
CN105748482A (zh) | 一种注射用头孢哌酮钠他唑巴坦钠药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200306 Address after: 322399 Zhejiang city of Jinhua province Panan County town Xinshi Road No. 270 Applicant after: PAN'AN COUNTY DAODIPANYAO TRADITIONAL CHINESE MEDICINE Research Institute Address before: 322305 No. third, 30 building, No. 88, Yao Cheng Road, new town, Panan, Jinhua, Zhejiang, China. Applicant before: JINHUA ZHIJI DRUG TECHNOLOGY PARTNERSHIP ENTERPRISE (L.P.) |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210510 Address after: No.3-6, 1st floor, No.3 Factory building, No.100 Nanhai Avenue, Haikou Free Trade Zone, Hainan 570000 Patentee after: Hainan Jinkang Pharmaceutical Co.,Ltd. Address before: 322399 No. 270 Xinshi Road, Anwen Town, Pan'an County, Jinhua City, Zhejiang Province Patentee before: PAN'AN COUNTY DAODIPANYAO TRADITIONAL CHINESE MEDICINE Research Institute |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No.3-6, 1st floor, No.3 Factory building, No.100 Nanhai Avenue, Haikou Free Trade Zone, Hainan 570000 Patentee after: Hainan guangshengyu Pharmaceutical Co.,Ltd. Address before: No.3-6, 1st floor, No.3 Factory building, No.100 Nanhai Avenue, Haikou Free Trade Zone, Hainan 570000 Patentee before: Hainan Jinkang Pharmaceutical Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Antibiotic composition and its preparation method Effective date of registration: 20230810 Granted publication date: 20200424 Pledgee: Hainan Bank Co.,Ltd. Haikou Wuyuanhe Branch Pledgor: Hainan guangshengyu Pharmaceutical Co.,Ltd. Registration number: Y2023980051707 |